Skip to main content

Table 1 Characteristics of the patient

From: Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer

Characteristics

Patient

Age

59 years

Gender

Male

Height

186 cm

Body weight

90 kg

Cancer type

Metastatic, hormone-refractory, poorly-differentiated prostate adenocarcinoma

Gleason score

8 (4 + 4)

Metastases

Residual primary tumor within the prostate bed with bilateral seminal vesicle infiltration and multiple lymph node as well as bone metastases

Stage of the disease (at initial diagnosis)

IV

Karnofsky index (at the time of this study)

90%

Relevant previous surgery

Cytoreductive Da-Vinci assisted robotic prostatovesiculectomy with bilateral regional lymphadenectomy

Other relevant treatment

Androgen deprivation therapy with NSAA (Bicalutamide) and GnRH analogue (Leuprorelin, Trenantone™)

PET/CT scan (152Tb-PSMA-617)

24 Days after PET/CT scan with 68Ga-PSMA-11

  1. NSAA non-steroidal antiandrogen, GnRH gonadotropin-releasing hormone